Metastatic Triple-Negative Breast Carcinoma Clinical Trials in Buffalo, New York

3 studies are recruiting for metastatic triple-negative breast carcinoma in Buffalo, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

    This phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER2+ breast cancer or HER+ Breast cancer that has spread to the brain (brain metastasis). Dendritic cell vaccines work by boosting the immune…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Roswell Park Cancer Institute, Buffalo, New York
    Locations
    3 in total
    Run by
    Roswell Park Cancer Institute

    See if you can join NCT04348747 on ClinicalTrials.gov

  2. Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

    This phase II trial tests how well propranolol and pembrolizumab work to cause tumor re-sensitization and therefore treatment in patients with triple negative breast cancer that has not responded to previous checkpoint inhibitor therapy (refractory), cannot be removed by surgery (unresectable) or h…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Roswell Park Cancer Institute, Buffalo, New York
    Locations
    2 in total
    Run by
    Emory University

    See if you can join NCT05741164 on ClinicalTrials.gov

  3. Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

    This phase II trial tests how well tamoxifen and pegylated liposomal doxorubicin works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that has spread to nearby tissue or lymph nodes (loca…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Roswell Park Cancer Institute, Buffalo, New York
    Run by
    Roswell Park Cancer Institute

    See if you can join NCT06434064 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.